Filter posts

ICYMI: The Hill Op-ed on Ending 340B Abuse

Writing in The Hill today, Ellen Weaver of the Palmetto Promise Institute and Lindsay Boyd …

BIO on CNBC: IPR System Weakens Medical Innovation

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on …

Here are the Facts about the IPR Kill Rate

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the …

Reflecting on July 2015: “The Ag Biotech Debate Was Front and Center”

Agri-Pulse recently published an op-ed titled “The Biotechnology Riddle” by Marshall Matz which outlined how …

Seventy Nine House Members Express Concern with H.R. 9

House leaders made the decision earlier this month to remove patent reform legislation from the …

Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?

In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first …

BIO Coalition Submits Patent Reform Letter to Congress

BIO, alongside a coalition of patent holders and inventors, submitted a letter to the chairmen …

House Ag Subcommittee Considers the Societal Benefits of Biotechnology

“Organic farmers do not need to demonize conventional farmers, we are one agriculture,” opened Ranking …

IPAB: Bad Medicine for Patient Care

The Independent Payment Advisory Board is bad medicine for patient care, deficit reduction and containing …

The Pivotal Role the Public Market Plays in Financing R&D

Growing innovators are the heart of our industry. Biotech small businesses face a dual struggle …